Assessing Healthcare Value Needs a Decentralized Approach
In Tomas Philipson’s latest Forbes.com op-ed, he examines the challenges of value assessment in the U.S. healthcare system and describes a decentralized approach to assessing value that better suits the U.S. context. Using IVI as an example, Philipson outlines several key criteria that a decentralized value assessment approach should meet in order to effectively link […]
A Discussion on Value-Based Pricing
IVI’s Director of Research, Jason Shafrin, contributes to an op-ed for The Washington Post‘s “In Theory Blog: How we should pay for cures, according to economics.” In the commentary, Dr. Shafrin uses the example of a cure for Alzheimer’s disease to illustrate how various stakeholders demand very different pricing structures, and how IVI is working to […]
The Demise of the Medicare Part B Demo
In a recent post on the IVI-sponsored Health Affairs blog series, Rachel Dolan looks at resistance to specific policies that attempt to move towards value-based reimbursement. Despite widespread bipartisan agreement that Medicare Part B should be paying for value, roadblocks are still formidable. Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs […]
Cost-Effectiveness 2.0: Poised for a Second Act?
Peter Neumann and co-author Gillian Sanders offer a new perspective on cost-effectiveness analysis in a new article published in the New England Journal of Medicine. Neumann and Sanders provide an overview of recent work and argue that cost-effectiveness analysis should be an essential component of healthcare decision-making. Read the full article here.
Discussing the Cures Act and New FDA Draft Guidance on Communication
In a post on the the IVI-sponsored Health Affairs blog series, Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payers and formulary committees about the real-world impacts of their products. Read the […]
Family Spillover Effects of Healthcare Treatments
In a recent post on the IVI-sponsored Health Affairs featured blog series, Anupam Jena and IVI Strategic Advisory Panel member, Sachin Kamal-Bahl, examine the spillover effects of healthcare for patients’ families. These family spillover benefits, they argue, may be significant. For example, a parent of a blind child would likely be willing to pay far more […]
21st Century Cures Act and Lowered Confidence in FDA-Approved Drugs and Devices
In a recent post on the IVI-sponsored Health Affairs featured blog series, Deborah Mazer and Gregory Curfman focus on provisions of the 21st Century Cures Act that will impact the FDA’s oversight of approved drugs and medical devices, including subtle changes to the approval procedures and a provision that permits-off label promotion of health care economic […]
Employers Can Take a Larger Role in Controlling Drug Costs
In a recent post on the IVI-sponsored Health Affairs featured blog series, Robert Galvin and Troyen Brennan make the case for employers and pharmacy benefit managers to challenge drug manufacturers’ pricing models as a means of keeping costs in check, particularly in regard to launch prices. They suggest a strategy in which employers and pharmacy benefit […]
Analyzing the Promise, Challenges and Limitations of the Precision Medicine Initiative and Cancer Moonshot
In a recent post on the IVI-sponsored Health Affairs featured blog series, Jonathan Darrow, Aaron Kesselheim, and Jessica Lasky-Su outline the goals and promise of the Precision Medicine Initiative and Cancer Moonshot. Although they also outline some of the key challenges and limitations, the authors recognize that there is a significant opportunity to translate the advances […]
Examining Value Frameworks and Key Considerations for Improvement
In a recent post on the IVI-sponsored Health Affairs featured blog series, the National Pharmaceutical Council’s Robert Dubois (also member of IVI Strategic Advisory Panel) and Kimberly Westrich examine current value assessment models’ readiness for use in healthcare decision-making. Applying NPC’s 35 Guiding Practices, they conclude that all existing frameworks possess individual strengths and weaknesses, but […]